FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, PhaseRx's Trailing 12-Month Free Cash Flow is $-12.84 Mil, and Market Cap is $0.00 Mil. Therefore, PhaseRx's FCF Yield % for today is 0.00%.
The historical rank and industry rank for PhaseRx's FCF Yield % or its related term are showing as below:
PZRXQ's FCF Yield % is not ranked *
in the Biotechnology industry.
Industry Median: -14.23 * Ranked among companies with meaningful FCF Yield % only.
The historical data trend for PhaseRx's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PhaseRx's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhaseRx's FCF Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PhaseRx's FCF Yield % distribution charts can be found below:
* The bar in red indicates where PhaseRx's FCF Yield % falls into.
PhaseRx FCF Yield % Calculation
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
PhaseRx's FCF Yield % for the fiscal year that ended in Dec. 2016 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhaseRx FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
PhaseRx FCF Yield % Related Terms
Thank you for viewing the detailed overview of PhaseRx's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PZRXQ has been successfully added to your 